Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $15.9 million.

  • Gyre Therapeutics' Total Current Liabilities rose 813.4% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year increase of 813.4%. This contributed to the annual value of $19.5 million for FY2024, which is 264.88% down from last year.
  • Per Gyre Therapeutics' latest filing, its Total Current Liabilities stood at $15.9 million for Q3 2025, which was up 813.4% from $16.9 million recorded in Q2 2025.
  • Gyre Therapeutics' Total Current Liabilities' 5-year high stood at $20.0 million during Q4 2023, with a 5-year trough of $1.6 million in Q3 2022.
  • Its 5-year average for Total Current Liabilities is $12.9 million, with a median of $14.7 million in 2024.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 9047.01% in 2022, then skyrocketed by 72535.05% in 2024.
  • Gyre Therapeutics' Total Current Liabilities (Quarter) stood at $14.2 million in 2021, then decreased by 13.58% to $12.2 million in 2022, then surged by 63.76% to $20.0 million in 2023, then dropped by 2.65% to $19.5 million in 2024, then dropped by 18.46% to $15.9 million in 2025.
  • Its Total Current Liabilities stands at $15.9 million for Q3 2025, versus $16.9 million for Q2 2025 and $19.0 million for Q1 2025.